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Abstract
Background: Overall pandemic A (H1N1) influenza vaccination rates remain low across all nations, including Japan. To
increase the rates, it is important to understand the motives and barriers for the acceptance of the vaccine. We conducted
this study to determine potential predictors of the uptake of A (H1N1) influenza vaccine in a cohort of Japanese general
population.
Methodology/Principal Findings: By using self-administered questionnaires, this population-based longitudinal study was
conducted from October 2009 to April 2010 among 428 adults aged 18–65 years randomly selected from each household
residing in four wards and one city in Tokyo. Multiple logistic regression analyses were performed. Of total, 38.1% of
participants received seasonal influenza vaccine during the preceding season, 57.0% had willingness to accept A (H1N1)
influenza vaccine at baseline, and 12.1% had received A (H1N1) influenza vaccine by the time of follow-up. After adjustment
for potential confounding variables, people who had been vaccinated were significantly more likely to be living with an
underlying disease (p=0.001), to perceive high susceptibility to influenza (p=0.03), to have willingness to pay even if the
vaccine costs $ US$44 (p=0.04), to have received seasonal influenza vaccine during the preceding season (p,0.001), and to
have willingness to accept A (H1N1) influenza vaccine at baseline (p,0.001) compared to those who had not been
vaccinated.
Conclusions/Significance: While studies have reported high rates of willingness to receive A (H1N1) influenza vaccine, these
rates may not transpire in the actual practices. The uptake of the vaccine may be determined by several potential factors
such as perceived susceptibility to influenza and sensitivity to vaccination cost in general population.
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Introduction
A new swine-origin influenza A (H1N1) emerged in early 2009
in Mexico and the United States and has since spread worldwide
[1]. On June 11, 2009, the World Health Organization (WHO)
declared the disease to be a pandemic phase 6, and the world
moved into the first global influenza pandemic in more than 40
years [2]. As of March 01, 2010, laboratory-confirmed cases had
been reported in more than 213 countries and territories with at
least 18,449 deaths worldwide [3]. In Japan, the first outbreak of
the novel influenza was confirmed in May 2009, and it became
pandemic in November of the same year [4,5]. This situation
triggered an extensive public health response, which included large
scale efforts to educate the general public about the pandemic,
including benefits and risks of vaccination and to develop strategies
to prevent transmission [6].
Vaccination is a primary public health measure to curb the
spread of A (H1N1) influenza pandemic due to the lack of innate
immunity as a result of the strain’s novelty [7]. In Japan, the
vaccination campaigns started in November 2009 targeting
prioritized populations including people living with underlying
diseases, pregnant women, children aged five years or younger,
and elderly people aged 65 years or older [8]. The national
standardized cost for the vaccination is approximately US$ 42 for
the first dose and US$ 30 for the second dose. People in prioritized
groups are, however, partially or fully subsidized by the local
government. Vaccination is provided at most healthcare facilities
such as hospitals, clinics, and public health centers. Local
government is responsible for dissemination of information
regarding the vaccination services through mass media such as
newspapers, town papers, posters, and internet.
Early vaccination against the virus is cost-effective and may
avert the deaths [9]. Public acceptance of the vaccination is thus a
crucial factor in controlling the pandemic [10]. However,
increasing the public acceptance of the vaccination may be more
difficult than addressing the technical and scientific challenges
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effective vaccine [11]. Considering that, despite unprecedented
public education campaigns and a worldwide pandemic, only
about 20% of adults in the United States have been vaccinated
against the pandemic influenza [6]. When fear of A (H1N1)
influenza was widespread, less than half of all adults were willing to
get vaccinated [12], and almost 20% of adults said they would not
consider getting vaccinated, even if people in their community
were sick or dying from the pandemic influenza [13]. To increase
A (H1N1) influenza vaccination rates, it is important to
understand the motives and barriers for the acceptance of the
vaccine.
Evidence has emerged regarding factors associated with
willingness to get A (H1N1) influenza vaccination. However, only
a few studies have examined the association of these factors with
the actual uptake of the vaccine, and most of these studies have
been conducted in key populations such as healthcare workers,
school teachers, people living with underlying diseases, elderly
people, and pregnant women. The identified factors consistently
reported in these studies include personal experience of getting
vaccinated against seasonal influenza [12,14,15], personal percep-
tion of high risk of getting infected by A (H1N1) influenza
[15,16,17], attitudes towards vaccine efficacy and safety
[6,18,19,20], perceived barriers to get vaccinated [21,22], and
social norms regarding A (H1N1) influenza vaccination [21].
These findings are important in response to the need for revising
or constructing a preparedness plan in early stage of the fight
against the pandemic A (H1N1) influenza. However, findings from
these studies are limited by the cross-sectional nature of the data.
To the best of our knowledge, one longitudinal study has been
conducted to explore the influencing factors related to the uptake
of A (H1N1) influenza vaccine among school teachers in the
United States [21]. To address this shortcoming, we conducted
this study to determine potential predictors of the actual uptake of
A (H1N1) influenza vaccination in a cohort of Japanese general
population.
Methods
Ethics statement
We sent a postal mail in which an information sheet and a
questionnaire were included to each selected person. In the
information sheet, we fully explained the nature and possible
consequences of the study and requested them to note if they were
willing to participate in the study. For those who did not want to
participate, we requested them to indicate on the sheet and return
it to us. The study protocol was reviewed and approved by the
Ethics Committee of the National Center for Global Health and
Medicine, Tokyo, Japan.
Sampling procedure
Baseline study was conducted in October 2009 and data for
follow-up was collected in April 2010. We used multi-stage
sampling strategy to select participants for this study. We first
randomly selected four wards out of 23 wards and two cities out of
26 cities comprising metropolitan Tokyo. Of these two selected
cities, one city refused participation. Number of towns in each
ward and city ranges from 20 to 155, and approximately 10% of
the towns were randomly selected. Probability proportional to size
sampling was used to select adults aged 18–65 years randomly
from the residential registries obtained from the municipal offices.
Figure 1 shows the flow of enrollment and retention of the study
participants. Out of 1,094 questionnaires distributed at baseline
survey, 600 were completed and returned, giving a response rate
of 54.8%. We further excluded 42 people who did not complete
the questionnaires by themselves, and 558 (51.0%) respondents
were included in baseline survey. Of these, 44 people declined to
remain in the cohort for follow-up. We invited 514 people for
follow-up, and 468 (42.8%) completed and returned the
questionnaires. We further excluded 30 people with missing data
in any measures and 10 people who did not complete the
questionnaires by themselves. We finally included 428 (39.1%)
people in the analyses.
Questionnaires and measurements
Self-administered, anonymous questionnaires were mailed to
participants in both baseline and follow-up survey by using the
same study protocol. The survey questionnaires were developed
based on measures adapted from previous studies and guidelines
recommended by the Japanese government and non-government
agencies. In baseline survey, we collected information regarding
socio-demographic characteristics, history of living with underly-
ing diseases, history of living with people in high risk groups,
Figure 1. Flow of enrollment and retention of the study
participants.
doi:10.1371/journal.pone.0018893.g001
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history of seasonal influenza infection during the current season
(2008–2009), knowledge on A (H1N1) influenza and its vaccine,
perception of risk of getting infected with A (H1N1) influenza,
perception of seriousness of pandemic A (H1N1) influenza,
preventive behavior against A (H1N1) influenza, attitudes towards
A (H1N1) influenza and its vaccine, and willingness to accept
vaccination against A (H1N1) influenza. In follow-up survey, we
additionally collected information regarding history of influenza
infection during the current season (2009–2010) and history of the
uptake of vaccine against seasonal influenza and A (H1N1)
influenza during the current season (2009–2010).
Willingness to accept vaccination against A (H1N1) influenza
was assessed by asking: ‘‘Do you plan to get A (H1N1) influenza
vaccine during this fall or winter if it becomes available?’’ with
three response options including ‘‘yes,’’ ‘‘no,’’ and ‘‘not sure.’’ The
uptake of influenza vaccine was assessed by asking the following
yes/no questions: ‘‘Did you receive seasonal influenza vaccine
during the last season (2008–2009)?’’; ‘‘Did you receive seasonal
influenza vaccine during this season (2009–2010)?’’; and ‘‘Did you
receive new swine A (H1N1) influenza vaccine during this season
(2009–2010)?’’ To assess risk perception, we asked: ‘‘Do you think
you are constitutionally susceptible to influenza infection?’’ using a
4-point scale that included ‘‘very high,’’ ‘‘high,’’ ‘‘not so high,’’ and
‘‘not high at all.’’ Regarding attitude towards vaccination,
participants were asked whether they feel anxious about the side
effects of swine A (H1N1) influenza vaccine with ‘‘a lot,’’ ‘‘some,’’
‘‘not much,’’ and ‘‘not at all’’ as response choices. To assess
willingness to pay for the vaccine, we asked: ‘‘Up to how much
would you pay for receiving swine A (H1N1) influenza vaccine?’’
with four response options including ‘‘free of charge,’’ ‘‘US$ 1t o
,22,’’ ‘‘US$ 22 to ,44,’’ and ‘‘$ US$ 44.’’
Regarding knowledge on A (H1N1) influenza and its vaccine,
we evaluated the correct responses to four yes/no questions
regarding modes of transmission, the fact that there have been
healthy people who had died from A (H1N1) influenza, people at
risk of A (H1N1) influenza, effectiveness of antiviral medicines
such as Tamiflu and Relenza against A (H1N1) influenza, and side
effects of vaccine against A (H1N1) influenza. To assess
participants’ preventive behavior, we asked whether participants
washed their hands after returning home during the preceding
week (yes/no).
For socio-demographic characteristics, participants reported their
age (continuous), gender (male or female), education attainment
(secondary/high school, college, or university/graduate school),
marital status (unmarried or married), employment status (employed
or unemployed), annual household income (,US$ 22,000,
US$ 22,000– ,55,000, US$ 55,000–111,000, $ US$ 111,000),
and whether the participant was living with children who go to
school (yes/no) and with people in high risk groups such as people
with an underlying disease, pregnant women, children aged five
yearsoryounger,and elderlypeopleaged 65yearsorolder(yes/no).
In this study, underlying diseases included chronic respiratory
diseases, chronic metabolic diseases, chronic heart diseases, kidney
diseases, and immunodeficiency diseases.
Data analyses
We compared characteristics of participants at baseline and
follow-up and characteristics of people who successfully completed
the study to those of people who participated in baseline but
refused to remain in the cohort or did not return the
questionnaires at follow-up by using x
2 test or Fisher’s Exact test
for categorical variables and student t-test for continuous variables.
Using cross tabulations, we assessed association between the
uptake of A (H1N1) influenza vaccine with several characteristics
of participants. We tested statistical significance of the association
by using Pearson’s x
2 test or Fisher’s exact test.
A multiple logistic regression model was then constructed to
determine potential predictors of the uptake of A (H1N1) influenza
vaccine. Socio-demographic characteristics and variables on
vaccination history, knowledge, perception, and behavior were
included in the model if they were associated with the uptake of A
(H1N1) influenza vaccine at a level of p#0.10 in bivariate analyses.
Two-sided p-values of ,0.05 were regarded as statistically
significant. We used SPSS version 17.0 (SPSS Inc, Chicago, IL)
for all the statistical analyses.
Results
Characteristics of participants
Characteristics of the participants at baseline and follow-up are
shown in Table 1. Of total, 58.9% were female with mean age of
42.6 years (SD =11.9 years). More than half (55.4%) of
participants had annual household income of $ US$55,000,
60.7% were married, 48.4% lived with people in high-risk groups,
and 9.6% had at least one underlying disease. Regarding
vaccination history, 38.1% received seasonal influenza vaccine
during the preceding season (2008–2009), 57.0% had willingness
to accept A (H1N1) influenza vaccine at baseline, and 12.1% had
been vaccinated by the time of follow-up. As shown in Table 1, no
significant difference was found in comparisons between charac-
teristics of respondents at baseline and follow-up. People who
completed the study (n=428) were significantly more likely to have
attained higher education (p=0.03) and to live with people in
high-risk groups (p=0.009) compared to those who were lost to
follow-up (n=90).
Bivariate analysis results
Table 2 and Table 3 show bivariate association of the uptake of
A (H1N1) influenza vaccine by the time of the follow-up with
socio-demographic characteristics and knowledge, attitudes, and
behavior toward A (H1N1) influenza and its vaccine. The
prevalence of the vaccination uptake was significantly higher
among women, people living with an underlying disease, people
with higher family income, people who perceived high suscepti-
bility to influenza, people who knew about the possible side effects
of A (H1N1) influenza vaccine, people who were willing to pay
even if the vaccine costs $ US$ 44, people who received seasonal
influenza vaccination during the preceding season (2008–2009),
and people who had willingness to accept A (H1N1) influenza
vaccine at baseline, relative to their comparison groups.
Multivariate analysis results
As shown in Table 4, after adjustment for potential confounding
variables, people who had been vaccinated were significantly more
likely to live with an underlying disease (p=0.001), to perceive
high personal susceptibility to influenza (p=0.03), to have
willingness to pay for the vaccine even if it costs $ US$ 44
(p=0.04), to have received seasonal influenza vaccination during
the preceding season (2008–2009) (p,0.001), and to have
willingness to accept A (H1N1) influenza vaccine at baseline
(p,0.001) compared to those who had not been vaccinated.
Discussion
This study represents a few attempts to identify influencing
factors associated with the actual uptake of A (H1N1) influenza
vaccine using a longitudinal design in general population. Several
Predictors of A (H1N1) Influenza Vaccination
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accept A (H1N1) influenza vaccine at baseline, receiving seasonal
influenza vaccine during the preceding season (2008–2009),
willingness to pay for the vaccine even if it costs $ US$ 44,
perceived high susceptibility to influenza, and living with an
underlying disease.
People who had willingness to accept A (H1N1) influenza vaccine
at baseline were more than four times more likely to get vaccinated
compared tothosewho had nowillingness.However,amongpeople
who were willing to get a shot of the vaccine at baseline, only 17.6%
had actually received it by the time of the follow-up. This finding
may raise concerns in respect to other potential factors that might
have diminished people’s final decision making on whether to take
the vaccinationat different stages of the pandemic. Because baseline
survey of this study was conducted when A (H1N1) influenza was at
its peak in Japan, we can expect that people’s willingness to get
vaccinated was strongly anchored and well-defined in general
population. The willingness might, however, be over-estimated, and
people may change their mind when the pandemic situation
Table 1. Characteristics of the participants at baseline and
follow-up.
Baseline (n=558) Follow-up (n=428)
Characteristics n% n%
Gender
Male 328 58.8 252 58.9
Female 230 41.2 176 41.1
Mean age in years (SD) 42.9 (12.5) 42.6 (11.9)
Marital status
Unmarried 222 40.0 168 39.3
Married 333 60.0 260 60.7
Employment status
Employed 436 78.4 334 78.0
Unemployed 120 21.6 94 22.0
Education attainment
Secondary/high school 189 34.4 161 37.6
College 136 24.7 106 24.8
University or higher 225 40.9 161 37.6
Annual household income (US$)
*
,22,000 65 11.9 46 10.7
22,000– ,55,000 192 35.2 145 33.9
55,000– ,111,000 214 39.2 173 40.4
$111,000 74 13.7 64 15.0
Having underlying diseases
{
Yes 57 10.3 41 9.6
No 499 89.7 387 90.4
Living with high-risk groups
{
Yes 258 46.3 207 48.4
No 298 53.5 221 51.6
Living with school-going children
1
Yes 193 34.6 153 35.7
No 363 65.2 275 64.3
History of influenza infection in 2009–2010
Yes - - 16 3.7
No - - 412 96.3
SD denotes standard deviation.
*Exchange rate: US$ 1 = ¥90.
{Underlying diseases included chronic respiratory diseases, chronic metabolic
diseases, chronic heart diseases, liver diseases, kidney diseases, and
immunodeficiency diseases.
{High-risk groups included people with an underlying disease, pregnant
women, children age five years or younger, and elderly people aged 65 years
or older.
1School-going children included primary school students to university students.
doi:10.1371/journal.pone.0018893.t001
Table 2. Bivariate association between participant’s
characteristics and the uptake of A (H1N1) influenza vaccine.
Total
(n=428)
Vaccine receivers
(n=52)
Characteristics nn (%) p-value
*
Socio-economic status
Gender
Male 176 14 (8.0) 0.03
Female 252 38 (15.1)
Age (years)
18–39 169 22 (13.0) 0.91
40–59 207 24 (11.6)
60–64 52 6 (11.5)
Marital status
Unmarried 168 18 (10.7) 0.47
Married 260 34 (13.1)
Education attainment
Secondary/high school 161 16 (9.9) 0.49
College 106 13 (12.1)
University or higher 161 23 (14.3)
Employment status
Employed 334 15 (16.0) 0.20
Unemployed 94 37 (11.1)
Annual household income (US$)
,22,000 46 5 (10.9) 0.005
22,000– ,55,000 145 17 (11.7)
55,000– ,111,000 173 14 (8.1)
$111,000 64 16 (25.0)
Having underlying diseases
{
Yes 41 12 (29.3) ,0.001
No 387 40 (10.3)
Living with high-risk groups
{
Yes 207 31 (15.0) 0.08
No 221 21 (9.5)
Living with school-going children
1
Yes 153 16 (10.5) 0.42
No 275 36 (13.1)
*p-values were based on x
2 test or Fisher’s Exact test.
{Underlying diseases included chronic respiratory diseases, chronic metabolic
diseases, chronic heart diseases, liver diseases, kidney diseases, and
immunodeficiency diseases.
{High-risk groups included people with an underlying disease, pregnant
women, children age five years or younger, and elderly people aged 65 years
or older.
1School-going children included primary school students to university students.
doi:10.1371/journal.pone.0018893.t002
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safety of the vaccine remained unavailable when vaccination
campaigns were launched. In Japan, A (H1N1) influenza vaccine
was not available for general population until January 2010 when
the number of A (H1N1) influenza cases was going down [23].
In line with previous studies [12,24], our results show that the
receipt of the novel A (H1N1) influenza vaccine were strongly
predicted by seasonal influenza vaccination in the preceding
season, suggesting common attitudinal motives and barriers to
both vaccines. The public is likely to share common concerns
regarding the pandemic and seasonal influenza vaccination,
Table 3. Knowledge, attitudes, and behavior towards A
(H1N1) influenza and its vaccine among vaccine receivers and
non-receivers.
Total
(n=428)
Vaccine receivers
(n=52)
Characteristics nn (%) p-value
*
Knowledge on A (H1N1) influenza
Modes of transmission
Correct 375 51 (13.6) 0.56
Incorrect 53 8 (15.1)
The fact that there have been healthy people who have died from A (H1N1)
influenza
Correct 333 42 (12.6) 0.58
Incorrect 95 10 (10.5)
People at risk of A (H1N1) influenza
Correct 416 51 (12.3) 0.56
Incorrect 12 1 (8.3)
Effectiveness of antiviral medicine such as Tamiflu or Relenza
Correct 324 41 (12.7) 0.59
Incorrect 103 11 (10.7)
Perception
Perceived susceptibility to influenza
Very high/high 95 21 (22.1) 0.001
Not so high/not high at all 333 31 (9.3)
Preventive behavior
Washing hand after returning home in the past week
Yes 377 43 (11.4) 0.20
No 51 9 (17.6)
Knowledge, attitudes, and behavior towards influenza vaccine
Knowledge about possible side effects of A (H1N1) influenza vaccine
Yes 303 44 (14.5) 0.02
No 125 8 (6.4)
Anxiety about adverse effects of A (H1N1) influenza vaccine
A lot/some 274 36 (13.1) 0.40
Not much/not at all 154 16 (10.4)
Willingness to pay for vaccine if it costs (US$)
Free of charge 44 2 (4.5) 0.006
1– ,22 160 15 (9.4)
22– ,44 179 23 (12.8)
$44 45 12 (26.7)
Receiving seasonal influenza vaccination during the last season (2008–2009)
Yes 163 41 (25.2) ,0.001
No 265 11 (4.2)
Willing to accept A (H1N1) influenza vaccine if it is available
Yes 244 43 (17.6) ,0.001
No 184 9 (4.9)
*p-values were based on x
2 test or Fisher’s Exact test.
doi:10.1371/journal.pone.0018893.t003
Table 4. Factors associated with the uptake of A (H1N1)
influenza vaccine in multivariate logistic regression model.
Characteristics
Adjusted OR
*
(95% CI) p-value
Socio-economic status
Gender
Male 2.04 (0.97–4.28) 0.06
Female Reference
Annual household income (US$)
{
,22,000 Reference
22,000– ,55,000 1.21 (0.40–3.71) 0.73
55,000– ,111,000 0.73 (0.23–2.35) 0.60
$111,000 2.82 (0.81–9.93) 0.10
Having underlying diseases
{
Yes 4.43 (1.90–10.33) 0.001
No Reference
Living with high-risk groups
1
Yes 1.34 (0.71–2.54) 0.37
No Reference
Perception
Perceived susceptibility to influenza
Very high/high 2.67 (1.12–6.37) 0.03
Not so high/not high at all Reference
Knowledge, attitudes, and behavior towards influenza vaccine
Knowledge about possible side effects of A (H1N1) influenza vaccine
Yes Reference
No 0.51 (0.22–1.16) 0.11
Willing to pay for vaccine if it costs (US$)
Free of charge Reference
1– ,22 1.80 (0.36–8.87) 0.47
22– ,44 2.33 (0.47–11.51) 0.30
$44 5.99 (1.07–33.46) 0.04
Receiving seasonal influenza vaccine during the last season (2008–2009)
Yes 7.33 (3.46–15.55) ,0.001
No Reference
Willing to accept A (H1N1) influenza vaccine if it is available
Yes 4.27 (1.94–9.39) ,0.001
No Reference
OR denotes odds ratio; CI denotes confidence interval.
*Other variables in the model included age, education attainment, marital
status, employment status, and anxiety about adverse effects of A (H1N1)
influenza vaccine.
{Exchange rate: US$ 1 = ¥90.
{Underlying diseases included chronic respiratory diseases, chronic metabolic
diseases, chronic heart diseases, liver diseases, kidney diseases, and
immunodeficiency diseases.
1High-risk groups included people with an underlying disease, pregnant
women, children age five years or younger, and elderly people aged 65 years
or older.
doi:10.1371/journal.pone.0018893.t004
Predictors of A (H1N1) Influenza Vaccination
PLoS ONE | www.plosone.org 5 April 2011 | Volume 6 | Issue 4 | e18893particularly in the areas of vaccine safety and side effects and
personal risks [25]. Strategies to improve the uptake of seasonal
influenza vaccine by general population should therefore be
adapted as a part of the pandemic preparedness plan, as
dissemination of correct information regarding vaccination may
be more difficult at the time of crisis [26].
Among reasons for the low A (H1N1) influenza vaccine coverage
rates, there may have been a lack of concern about the individual
risk, which may translate into a lack of willingness or urgency to get
vaccinated, particularly if there is mistrust of information provided
by public health or government authorities [25]. There may have
alsobeen confusion regardingthe differencesbetween the pandemic
and seasonal influenza as well as their vaccines [24]. People may
believe that A (H1N1) influenza is as mild as seasonal influenza, and
its vaccine may be necessary only for people in high risk groups.
Without clarification of the misunderstanding, people might see A
(H1N1) influenza as a relatively mild disease and think that it may
not worth the risk to get vaccinated as the vaccine has not been
thoroughly tested for efficacy and safety.
People may perform a sort of trade-off between perceived risk
and perceived benefit regarding the vaccine uptake. In this study,
the majority (77.8%) of participants perceived their susceptibility
to A (H1N1) influenza as ‘‘not so high’’ or ‘‘not high at all,’’ and
those in this category were almost three times less likely to get
vaccinated compared to those who perceived their susceptibility as
‘‘high or very high.’’ Meanwhile, more than two thirds of them
were anxious about adverse effects of the vaccine. This suggests
that perceived risks may exceed perceived benefit. In addition, the
acceptability of A (H1N1) influenza vaccine was sensitive to cost,
although Japan is a fairly affluent country with a high degree of
vigilance for influenza. People who were willing to pay for the
vaccine even if it costs $ US$ 44 were almost seven times more
likely to get vaccinated compared to those who were willing to get
vaccinated only if it is available for free. Such a cost sensitivity may
also be true for the case of seasonal influenza vaccine for which, in
Japan, people have to pay up to approximately US$ 25 to US$ 60
[8]. We may expect that this sensitivity could even be higher in
developing countries and in those countries where people may feel
less anxious about A (H1N1) influenza.
It is worth noting that some important factors, such as anxiety
about adverse effects of A (H1N1) influenza vaccine and living
with people in high risk groups, did not retain their significant
association with the uptake of A (H1N1) influenza vaccine in this
study. Concerns about vaccine safety and side effects have been
consistently reported as a potential determinant of willingness to
get vaccinated and/or the uptake of the vaccine [25,27], while
people living with high risk groups have been prioritized as a target
group for vaccination campaigns [28]. These unexpected findings
may be explained by the timing when the study was conducted,
which was in a relatively later stage of A (H1N1) influenza vaccine
progress, and the different definition of terms used in the current
study. Our definition of ‘‘high-risk groups’’ covered a wide range
of people including people living with underlying diseases,
pregnant women, small children, and elderly people.
The major strengths of this study include the longitudinal design
with the ability to document not only people’s willingness to accept
A (H1N1) vaccine but also their actual practice of receiving the
vaccine in six-month follow-up. Moreover, we were able to control
for the effects of several potential confounding factors.
Several limitations of this study should also be noticed. First, our
findings were limited by the validity of self-reporting measures,
which may lead to either under-reporting or over-reporting due to
social desirability or conformity. Second, the relatively low
response rate (54.8%) may have resulted in a biased sample and
become potential threats to the generalizability of the findings to
the whole population. This response rate, however, is comparable
to or even higher than that of many mailing or telephone surveys
in other countries [12,16,29,30]. Third, although the measure of
each construct was carefully developed, the unknown validity and
reliability of the study instruments may be of concern, and could
result in the difficulties in making cross-population comparisons.
Forth, our relatively small sample size may not sufficiently
powerful to detect modest association. The final limitation
concerns the timing of the survey that might have led to both an
overestimate of willingness to receive the vaccination and an
underestimate of the vaccine coverage rate among Japanese adult
population since the controversy about the efficacy, safety, and
necessity of the pandemic A (H1N1) influenza vaccine was
growing over the study period.
Despite these limitations, this study contributes to the literature
in several ways. While studies have reported high rates of
willingness to receive A (H1N1) influenza vaccine, these rates
may not transpire in the actual practices among general
population. The uptake of the pandemic A (H1N1) influenza
vaccine may be determined by several potential factors such as
perceived susceptibility to influenza and sensitivity to vaccination
cost. Although cultural differences could affect the acceptance of
vaccines in general [31], we believe that there are common
motives and barriers to the uptake of A (H1N1) influenza vaccine
that exist across geographical regions and racial groups. Findings
of this study can therefore serve as a reference for the development
of strategies to improve the uptake of the pandemic A (H1N1)
influenza vaccine in general population in Japan as well as in
other countries.
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